Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
作者： Eric Van Cutsem , Claus-Henning Köhne , Erika Hitre , Jerzy Zaluski , Chung-Rong Chang Chien
关键词:
摘要: Background We investigated the efficacy of cetuximab plus irinotecan, fluorouracil, and leucovorin (FOLFIRI) as first-line treatment for metastatic colorectal cancer sought associations between mutation status KRAS gene in tumors clinical response to cetuximab. Methods randomly assigned patients with epidermal growth factor receptor–positive unresectable metastases receive FOLFIRI either alone or combination The primary end point was progression-free survival. Results A total 599 received FOLFIRI, alone. hazard ratio survival cetuximab–FOLFIRI group compared 0.85 (95% confidence interval [CI], 0.72 0.99; P=0.048). There no significant difference overall two groups (hazard ratio, 0.93; 95% CI, 0.81 1.07; P=0.31). a interaction ...
pagesperso-orange.fr
researchgate.net 参考文章(33)
WILLIAM A. GROVE, Statistical Methods for Rates and Proportions, 2nd ed American Journal of Psychiatry. ,vol. 138, ,(1981) , 10.1176/AJP.138.12.1644-A
Nadir Arber, Itzhak Shapira, Jaccob Ratan, Baruch Stern, Hanina Hibshoosh, Menhachem Moshkowitz, Marillin Gammon, Ina Fabian, Zamir Halpern, Activation of c-K-ras mutations in human gastrointestinal tumors. Gastroenterology. ,vol. 118, pp. 1045- 1050 ,(2000) , 10.1016/S0016-5085(00)70357-X
Eric Van Cutsem, Karen Geboes, The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer Best Practice & Research in Clinical Gastroenterology. ,vol. 21, pp. 1089- 1108 ,(2007) , 10.1016/J.BPG.2007.10.020
E. L. Kaplan, Paul Meier, Nonparametric Estimation from Incomplete Observations Springer Series in Statistics. ,vol. 53, pp. 319- 337 ,(1992) , 10.1007/978-1-4612-4380-9_25
F Di Fiore, F Blanchard, F Charbonnier, F Le Pessot, A Lamy, M P Galais, L Bastit, A Killian, R Sesboüé, J J Tuech, A M Queuniet, B Paillot, J C Sabourin, F Michot, P Michel, T Frebourg, Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. British Journal of Cancer. ,vol. 96, pp. 1166- 1169 ,(2007) , 10.1038/SJ.BJC.6603685
D. M. Parkin, F. Bray, J. Ferlay, P. Pisani, Global cancer statistics, 2002. CA: A Cancer Journal for Clinicians. ,vol. 55, pp. 74- 108 ,(2005) , 10.3322/CANJCLIN.55.2.74
Chiung-Yu Chen, Shu-Chu Shiesh, Sheu-Jen Wu, Rapid Detection of K-ras Mutations in Bile by Peptide Nucleic Acid-mediated PCR Clamping and Melting Curve Analysis: Comparison with Restriction Fragment Length Polymorphism Analysis Clinical Chemistry. ,vol. 50, pp. 481- 489 ,(2004) , 10.1373/CLINCHEM.2003.024505
C. Bokemeyer, E. Staroslawska, A. Makhson, I. Bondarenko, J.T. Hartmann, Y. Shelygin, O. Kolesnik, C. Volovat, A. Zubel, P. Koralewski, 3004 ORAL Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) in the first-line treatment of metastastic colorectal cancer (mCRC): a large-scale phase II study, OPUS Ejc Supplements. ,vol. 5, pp. 236- ,(2007) , 10.1016/S1359-6349(07)70932-1
Eric Van Cutsem, Marc Peeters, Salvatore Siena, Yves Humblet, Alain Hendlisz, Bart Neyns, Jean-Luc Canon, Jean-Luc Van Laethem, Joan Maurel, Gary Richardson, Michael Wolf, Rafael G. Amado, Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Journal of Clinical Oncology. ,vol. 25, pp. 1658- 1664 ,(2007) , 10.1200/JCO.2006.08.1620
D. Arnold, T. Höhler, C. Dittrich, F. Lordick, T. Seufferlein, J. Riemann, E. Wöll, T. Herrmann, A. Zubel, H.-J. Schmoll, Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group Annals of Oncology. ,vol. 19, pp. 1442- 1449 ,(2008) , 10.1093/ANNONC/MDN150